Condition

Resistant Breast Cancer

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions5

Lead sponsors shown2

Clinical trials

2 shown

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNCT07729046 · 2027-07-01

NOT_YET_RECRUITING

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast CancerNCT03958721 · 2019-07-18

COMPLETED

Common interventions

CapecitabineDRUG1 CDK4/6 + Endocrine therapyDRUG1 Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrantDRUG1 Neratinib + endocrine therapyDRUG1 RadiotherapyRADIATION1

Leading sponsors

A Bapsi Chakravarthy, MD1 University of California, San Diego1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

Phase mix

PHASE11

PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.